Heart Fail Rev
-
Publication Venue For
- Skeletal muscle abnormalities in heart failure with preserved ejection fraction.. 28:157-168. 2023
- Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction.. 27:741-753. 2022
- Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion.. 26:1529. 2021
- Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions.. 23:609-629. 2018
- Expanded algorithm for managing patients with acute decompensated heart failure.. 23:597-607. 2018
- Redefining the role of biomarkers in heart failure trials: expert consensus document.. 22:263-277. 2017
- Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.. 21:309-322. 2016
- Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.. 21:95-102. 2016
- Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review.. 20:643-653. 2015
- Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations.. 20:393-400. 2015
- Site selection for heart failure clinical trials in the USA.. 20:375-383. 2015
- Water and sodium in heart failure: a spotlight on congestion.. 20:13-24. 2015
- Lipids, statins, and clinical outcomes in heart failure: rethinking the data.. 19:695-698. 2014
- Anatomy of the obesity paradox in heart failure.. 19:621-635. 2014
- Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.. 19:135-152. 2014
- Anticoagulation in heart failure: current status and future direction.. 18:797-813. 2013
- The immunological axis in heart failure: importance of the leukocyte differential.. 18:835-845. 2013
- Soluble guanylate cyclase: a potential therapeutic target for heart failure.. 18:123-134. 2013
- Patient selection for mechanical circulatory support.. 18:27-34. 2013
- Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy.. 17:387-394. 2012
- Loop diuretics in heart failure.. 17:305-311. 2012
- Significance of hyponatremia in heart failure.. 17:17-26. 2012
- Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions.. 16:477-480. 2011
- Biomarker guided therapy for heart failure: focus on natriuretic peptides.. 15:351-370. 2010
- Multi-marker strategies in heart failure: clinical and statistical approaches.. 15:343-349. 2010
- Relaxin, a pleiotropic vasodilator for the treatment of heart failure.. 14:321-329. 2009
- Role of guanylate cyclase modulators in decompensated heart failure.. 14:309-319. 2009
- Vasodilators in the treatment of acute heart failure: what we know, what we don't.. 14:299-307. 2009
- Introduction: Vasopressin therapy.. 14:57-58. 2009